Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Share price

Really what has changed? What has run the price down to the current lows. Our patents have passed through the USPTO gauntlet. We have been in litigation since 2008 so we knew that was always an issue. The T3 first tried to crush the patents through exparte re-examinations this legal strategy failed them. Now they are trying the non infringer strategy will this fail as well? If they didn't infringe in the first place why spend so much time trying to squash the patents?

Leckrone has been called out, our BOD has been called out. Shouldn't this be good for our shareprice? We now know what alot of us suspected, that things were not quite on the up and up. All the non-infringement testimony will be sealed, if we win or lose will other companies on notice be able to tell that they are infringers or not? Or will they sign licensing agreements to avoid litigation?

If our Company managed information better I think we would be doing better a lot better.

The feeling that BOD is not on our side is the biggest culprit to the demise of the SP at least that is how I feel.

IMO

Share
New Message
Please login to post a reply